Natural history of hepatitis B and outcomes after liver transplantation

Clinics in Liver Disease

Volumn 7, Issue 3, 2003, Pages 521-536

  Huang, Mary Ann ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS E ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE;

CHRONIC HEPATITIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PREVALENCE; REINFECTION; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIRUS TRANSMISSION;

EID: 0041833554     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00054-0     Document Type: Review

References (82)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. Lok ASF, McMahon BJ. Chronic Hepatitis B. Hepatology 2001;34:1225-41.
3. Magnius LO, Norder H. Subtypes, genotypes, and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
4. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
5. Lindh M, Hannoun C, Dhillon AP, et al. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179: 775-82.
6. Tsubota A, Arase Y, Ren F, et al. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001;65:257-65.
7. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122: 1756-62.
8. Hadziyannis SJ, Vassilopoulous D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
9. Tong SP, Li JS, Vitvtiski L, et al. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology 1992; 191:237-45.
10. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91.
11. Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-8.
12. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160: 577-82.
13. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus in preschool children in Taiwan. J Infect Dis 1982;146:198-204.
14. Corsaget P, Yvonnet B, Chotard J, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22:1-5.
15. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
16. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
17. Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis e antigen before 3 years of age. Hepatology 1995;22:1387-92.
18. Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000;15(Suppl):E15-9.
19. Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-9.
20. Sterneck M, Kalinina T, Gunther S, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998;28:1390-7.
21. Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infection. Gastroenterology 1993;105:1529.
22. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404.
23. Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549.
24. Chan HLY, Tsang SWC, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis b virus infection. Am J Gastroenterol 2002;97:406-12.
25. Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998;27:1377.
26. Chang MH. Natural history of hepatitis B infection in children. J Gastroenterol Hepatol 2000; 15:E11-9.
27. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:739.
28. Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-9.
29. Hsu HC, Su IJ, Lai MY, et al. Biological and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987;5:45.
30. Maruyama T, Lino S, Koike K, et al. Serology of acute exacerbation in coronic hepatitis B virus infection. Gastroenterology 1993;105:1141.
31. Liaw YF, Pao CC, Chu CM, et al. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconvension in chronic type B hepatitis. Hepatology 1987;7:1.
32. Lok ASF, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839-43.
33. Alward WLM, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-9.
34. Chu CM, Liaw YF, Pao CC, et al. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HbsAg carriers. Hepatology 1989;9:452.
35. Sheen IS, Liaw YF, Tai DI, et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985;89:732.
36. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10
37. Lok AS, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110.
38. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8.
39. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72.
40. Lok ASF, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B (HBV) virus infection: Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34.
41. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of coronic hepatitis B virus infection. Gastroenterology 1984;86:230-3.
42. Chan HLY, Leung NWY, Hussain M, et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000;31:763-8.
43. Di Marco V, lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999;29:971-5.
44. Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. NEJM 1991;324:1699-1704.
45. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36: 263-70.
46. Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants, and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991; 13:627.
47. Huo Ti, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface artigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-6.
48. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a perspective observation in 2215 patients. J Hepatol 1998; 28:930-8.
49. Laskus T, Radkowski M, Lupa E, et al. Prevalence of markers of hepatitis viruses in outpatient alcoholics. J Hepatol 1992;15:174.
50. Conjeevaram HS, Lok ASF. Occult hepatitis B virus infection: A hidden menace? Hepatology 2001;34:204-6.
51. Sheen IS, Liaw YF, Lin DY, et al. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: A multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994;17:358.
52. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
53. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
54. Fattovich G, Brollo L, Giustina G, Noventa F, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
55. Hui AY, Chan HL, Leung NW, et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 2002;34: 569-72.
56. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994;21:656-66.
57. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. NEJM 1996;334:1422-7.
58. Liaw YF, Lin DY, Chen TJ, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235-41.
59. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
60. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77.
61. Lok AS, Lai CL. Factors determining the development of hepatocellular carcinoma in hepatitis B surface antigen carriers. A comparison between families with clusters and solitary cases. Cancer 1988;61:1287-91.
62. Teo EK, Han SH, Terrault N, et al. Liver transplantation in patients with hepatitis B virus infection: Outcome in Asian versus White patients. Hepatology 2001;34:126-32.
63. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994;74:2442-8.
64. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362-6.
65. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420-6.
66. Fontana RJ, Hann HWL, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-27.
67. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991;13:619.
68. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104.
69. Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992;102:956.
70. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989;321:1092.
71. McMillan JS, Shaw T, Angus PW, et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995;22:36.
72. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988;167:630.
73. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990;12:364.
74. Han SHB, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6:741-8.
75. Marzan A, Alizzoni M, Debemardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10.
76. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-6.
77. Fontana R, Keeffe E, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B Liver Transpl 2002;8: 433-9.
78. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-73.
79. Perrillo R, Schiff E, Yoshida E, et al. Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
80. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-35.
81. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842.
82. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24: 1327-33.